OneSource™ Can Help You During Open Enrollment

Whether you’re on Soliris® or considering Soliris, an Alexion Nurse Case Manager can help answer questions about health insurance and explain your choices

Already on Soliris?

During open enrollment, your Alexion Nurse Case Manager can answer your questions about changes in your insurance and how that might affect your Soliris coverage. In order to continue uninterrupted treatment, contact OneSource if there are any changes to your coverage, such as:

  • Any change to your health insurance
  • Change of employment
  • Change of residence
  • Change of treatment site or treating physician
  • Hospitalizations
  • Going away to school

Considering Soliris?

An Alexion Nurse Case Manager can help answer your questions about health insurance coverage options. Your Nurse Case Manager can also provide you with information and educational resources related to PNH and Soliris.



Soliris is indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.




IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.

This site is intended for US audiences only. © Copyright and Terms of Use 1999 - 2010 Alexion Pharmaceuticals. All rights reserved. Site Map | Privacy Policy | Legal | Glossary
SOLUS03-0153-001